Integrated Drug Discovery

CADD

Argenta’s CADD group is directed by Dr David Clark, and plays many roles within our integrated discovery approach.

These include ligand- and structure-based drug design, protein modelling and QSAR, including predictive/in silico ADMET. We utilise a comprehensive range of industry standard software combined with computational approaches developed in-house.

We have particular expertise in virtual screening including:

• Docking into receptor/enzyme active sites
• Pharmacophore identification & 3-D pharmacophore searching
• 2-D & 3-D similarity searching using FTrees and FlexS (developed by BiosolveIT)

Using these approaches, we have undertaken successful hit-finding projects against a variety of different target classes.

For more information on our CADD capabilities please contact us.